Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RBDr. Robert Bast
    Leading Voice

    Dr. Robert Bast

    Medical Oncology · Breast Oncology
    The University of Texas MD Anderson Cancer Center
    robertbast
    Houston, TX, USA

    Research

    CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation

    2025

    Via Clinical Cancer Research

    Research

    DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/FAK/AKT Signaling Pathway

    2025

    Via Cells

    Research

    Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers

    2025

    Via Clinical Proteomics

    Research

    DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas

    2024

    Via Autophagy

    Research

    Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer

    2024

    Via British Journal of Cancer

    Research

    Normal Risk Ovarian Screening Study: 21-Year Update

    2024

    Via Journal of Clinical Oncology

    Research

    A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer

    2024

    Via Drug Resistance Updates

    Research

    IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer

    2024

    Via BMC Medicine

    Research

    A metabolite-based liquid biopsy for detection of ovarian cancer

    2024

    Via Biomarker Research

    Research

    Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy

    2024

    Via Molecular Cancer Research

    Research

    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

    2023

    Via Oncogene

    Research

    SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

    2022

    Via Journal of Clinical Investigation

    Research

    SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK

    2022

    Via Molecular Oncology

    Research

    Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy

    2022

    Via Journal of the American Chemical Society

    Research

    Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics

    2022

    Via JAMA Network Open